Provided is the use of oral formulations of cytidine analogs in the treatment of cancer. In a preferred embodiment an oral formulation of the cytidine analog 5-azacytidine is used in combination with a platinum agent, such as carboplatin, for the treatment of non-small cell lung cancer (NSCLC).